

Confirmed Speakers

Confirmed Speakers

L01 - GPCR-ligand Structures through the Looking Glass: Computer-Aided Prediction of GPCR-Ligand Interactions



Dr Chris DE GRAAF
(VU UNIVERSITY AMSTERDAM, Cambridge, United Kingdom)

L03 - Dual A2A-NR2B Antagonists: Potential for Unprecedented Activity in Parkinson's Disease



Mr Joël MERCIER
(UCB, BRAINE-L'ALLEUD, Belgium)

L05 - Developing Ligands to Validate the Role of Receptors for Long-chain Fatty Acids in the Treatment of Type II Diabetes



Prof. Graeme MILLIGAN
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

L06 - Positive Allosteric Modulators of mGlu2 Receptors for the Treatment of CNS Disorders



Dr Daniel OEHLRICH
(JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, Beerse, Belgium)

L04 - Biased Ligands, Allosteric Modulation: New Technological Approaches



Dr Stephan SCHANN
(DOMAIN THERAPEUTICS, Strasbourg, France)

L02 - Nanobodies to Study GPCR Transmembrane Signaling: From Structures to Function to Drugs



Prof. Jan STEYAERT
(VUB, Brussels, Belgium)

Oral Communications

OC03 - Identification of Modulators for SUCNR1 BY Screening of a SOSA Library with a Bioluminescent cAMP Assay

Mrs Julie GILISSEN
(ULG, Liege, Belgium)

OC01 - Discovery of Donecopride: Design of Dual 5-HT4R Agonists/AChE Inhibitors Multi-Target Directed Ligands for Alzheimer's Disease Treatment



Prof. Christophe ROCHAIS
(UNIVERSITY OF CAEN, Caen, France)

Confirmed Speakers

OC02 - Novel Histamine H1-Receptor Fluorescent Antagonists for the Study of Receptor-Ligand Interactions



Dr Leigh STODDART
(UNIVERSITY OF NOTTINGHAM , Nottingham, United Kingdom)